Skip to main content
SpringerLink
Log in

GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes

  • Chapter
  • First Online:
Endocrinology and Diabetes

  • 1234 Accesses

Abstract

The incretin-based therapies are represented by glucagon-like peptide 1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase-IV inhibitors (DPP-IV). These new therapies have revolutionized the treatment of T2DM, intervening in a pathophysiological pathway not previously addressed. This chapter will review pathophysiology, mechanism of action, and indications for the use of GLP-1 RA.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Nauck MA, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46–52.

    Article  CAS  PubMed  Google Scholar 

  2. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–57.

    Article  CAS  PubMed  Google Scholar 

  3. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.

    Article  CAS  PubMed  Google Scholar 

  4. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7–36)amide is transformed to glucagon-like peptide-1-(9–36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology. 1999;140:5356–63.

    Article  CAS  PubMed  Google Scholar 

  5. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab. 2009;94:1843–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Perfetti R, Merkel P. Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. Eur J Endocrinol. 2000;143:717–25.

    Article  CAS  PubMed  Google Scholar 

  7. Wang Y, Perfetti R, Greig NH, Holloway HW, DeOre KA, et al. Glucagonlike peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest. 1997;99:2883–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270–6.

    Article  CAS  PubMed  Google Scholar 

  9. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem. 2003;278:471–8.

    Article  CAS  PubMed  Google Scholar 

  10. Cernea S, Raz I. Therapy in the early stage: incretins. Diabetes Care. 2011;34:S264–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87:1239–46.

    Article  CAS  PubMed  Google Scholar 

  12. Lee YS, Shin S, Shigihara T, Hahm E, Liu MJ, et al. Glucagonlike peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes. 2007;56:1671–9.

    Article  CAS  PubMed  Google Scholar 

  13. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24:275–86.

    Article  CAS  PubMed  Google Scholar 

  14. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology. 2006;43:173–81.

    Article  CAS  PubMed  Google Scholar 

  15. Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res. 2011;2011:279530.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009;53:501–10.

    Article  CAS  PubMed  Google Scholar 

  17. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010;59:1030–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Meier JJ. The contribution of incretin hormones to the pathogenesis of type 2 diabetes. Best Pract Res Clin Endocrinol Metab. 2009;23:433–41.

    Article  CAS  PubMed  Google Scholar 

  19. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267:7402–6.

    Article  CAS  PubMed  Google Scholar 

  20. http://www.fda.gov/drugs/drugsafety/postmarket. Accessed 21 Jul 2012.

  21. Iltz JL, Baker DE, Setter SM, Keith CR. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther. 2006;28:S56–8.

    Article  Google Scholar 

  22. Unger JE. Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus. Mayo Clin Proc. 2010;85:S38–49.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism. 2001;50:583–9.

    Article  CAS  PubMed  Google Scholar 

  24. http://www.fda.gov/drus/drugssafety/UCM289869. Accessed 21 Jul 2012.

  25. Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2006;8:419–28.

    Article  CAS  PubMed  Google Scholar 

  26. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376:431–9.

    Article  PubMed  Google Scholar 

  27. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628–35.

    Article  CAS  PubMed  Google Scholar 

  28. Gallwitz B, Guzman J, Dotta F, Guerci B, Simó R, et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet. 2012;379:2270–8.

    Article  CAS  PubMed  Google Scholar 

  29. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150–6.

    Article  CAS  PubMed  Google Scholar 

  30. Butler PC, Dry S, Elashoff R. GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care. 2010;33:453–5.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Ussher JE, Drucker JE. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33:187–215.

    Article  CAS  PubMed  Google Scholar 

  32. Patil HR, Al Badarin FJ, Al Shami HA, Bhatti SK, Lavie CJ, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110:826–33.

    Article  CAS  PubMed  Google Scholar 

  33. Blevins T, Pullman J, Malloy J, Yan P, Taylor K, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:1301–10.

    Article  CAS  PubMed  Google Scholar 

  34. De Fronzo RA, Triplitt C, Qu Y, Lewis M, Maggs D, Glass LC. Effects of exenatide plus rosiglitazone on β-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care. 2010;33(5):951–7.

    Article  Google Scholar 

  35. Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, et al. One-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients a randomized, controlled trial. Diabetes Care. 2009;32:762–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, et al. Use of twice-daily exenatide in basal insulin–treated patients with type 2 diabetes: a randomized. Controlled Trial Ann Intern Med. 2011;154:103–12.

    Article  PubMed  Google Scholar 

  37. Nauck MA, Duran S, Kim D, Johns D, Northrup J, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50:259–67.

    Article  CAS  PubMed  Google Scholar 

  38. Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral anti-diabetes agents. Diabetes Care. 2007;30:2767–72.

    Article  CAS  PubMed  Google Scholar 

  39. Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol. 2009;297:137–40.

    Article  CAS  PubMed  Google Scholar 

  40. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39–47.

    Article  CAS  PubMed  Google Scholar 

  42. Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473–81.

    Article  CAS  PubMed  Google Scholar 

  44. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52:2046–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care. 2009;32:1224–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151:1473–86.

    Article  PubMed  Google Scholar 

  47. Hegedüs L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab. 2011;96:853–60.

    Article  PubMed  Google Scholar 

  48. Pi-Sunyer X, Astrup A, Fujioka K. et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.

    Article  PubMed  Google Scholar 

  49. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37:2159.

    Article  CAS  PubMed  Google Scholar 

  50. Umpierrez G, Tofé Povedano S, Pérez Manghi F, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37:2168.

    Article  CAS  PubMed  Google Scholar 

  51. Weinstock RS, Guerci B, Umpierrez G, et al. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17:849.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Marso SP, Bain SC, Consoli A, Daniels GH, Brown-Frandsen K. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2017;2017(376):890–2.

    Google Scholar 

  53. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2012;35:1364–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Field AE, Coakley EH, Must A, Spadano JL, Laird N, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 2001;161:1581–6.

    Article  CAS  PubMed  Google Scholar 

  55. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36:843–54.

    Article  CAS  Google Scholar 

  57. Petersen AB, Christensen M. Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus. Diabetes Metab Synd Obes. 2013;6:217–31.

    Article  CAS  Google Scholar 

  58. Sorli C, Harashima S-I, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–60.

    Article  CAS  PubMed  Google Scholar 

  59. Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341–54.

    Article  PubMed  Google Scholar 

  60. Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, et al. Sustain 3. 2017:1–9.

    Google Scholar 

  61. Aroda VR, Bain SC, Cariou B, Piletič M, Rose L, Axelsen M, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–66.

    Article  CAS  PubMed  Google Scholar 

  62. Rodbard H, Lingvay I, Reed J, et al. Efficacy and safety of semaglutide once-weekly vs placebo as add-on to basal insulin alone or in combination with metformin in subjects with type 2 diabetes (SUSTAIN 5) ||ePoster #766. 2016 [cited 2016 Nov 5]. Available from: http://www.easdvirtualmeeting.org/resources/efficacy-and-safety-of-semaglutide-once-weekly-vs-placebo-as-add-on-to-basal-insulin-alone-or-in-combination-with-metformin-in-subjects-with-type-2-diabetes-sustain-5-871c6042-fbff-48ef-aec0-e9b358e10195

  63. Kaul S. Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 trials. Diabetes Care. 2017;40(7):821–31.

    Article  CAS  PubMed  Google Scholar 

  64. Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol [Internet]. 2018;8587(Sustain 7):1–12. Available from: http://linkinghub.elsevier.com/retrieve/pii/S221385871830024X.

    Google Scholar 

  65. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med [Internet]. 2016;375(19):1834–44. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1607141.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Agamenon Magalhães Hospital,University of Pernambuco Medical School, Recife, PE, Brazil

    Francisco Bandeira

  2. Endocrinology and Metabolism, Osvaldo Cruz Hospital—University of Pernambuco, Recife, PE, Brazil

    Fábio Moura

  3. Endocrinology, Agamenon Magalhaes Hospital, Jaboatao dos Guararapes, Recife, PE, Brazil

    Bruna Burkhardt Costi

  4. Agamenon Magalhaes Hospital, Department of Endocrinology and Metabolism, Recife, PE, Brazil

    Ana Carolina S. M. Cardoso

Authors
  1. Francisco Bandeira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fábio Moura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bruna Burkhardt Costi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ana Carolina S. M. Cardoso
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Agamenon Magalhães Hospital, University of Pernambuco Medical School, Recife, Pernambuco, Brazil

    Francisco Bandeira

  2. Division of Endocrinology, Mayo Clinic College of Medicine, Rochester, MN, USA

    Hossein Gharib

  3. School of Medicine, University of Pernambuco, Recife, Brazil

    Luiz Griz

  4. School of Medicine, University of Maranhao, Sao Luis, Brazil

    Manuel Faria

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bandeira, F., Moura, F., Costi, B.B., Cardoso, A.C.S.M. (2022). GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes. In: Bandeira, F., Gharib, H., Griz, L., Faria, M. (eds) Endocrinology and Diabetes. Springer, Cham. https://doi.org/10.1007/978-3-030-90684-9_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-90684-9_31

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-90683-2

  • Online ISBN: 978-3-030-90684-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation